Problem Session (2) -Answer-

2017/5/27 Takehiro Kato

Topics: Total synthesis of branimycin

0. Introduction

Isolation

Isolated from Actinomycete GW 60/1571 Speitling, M. Ph. D. Thesis. University of Göttingen, **1998**. (Laatsch group)



Biological activity

active against *Escherichia Coli*, *Bacillus subtilis*, *Staphylococus aureus*, and in particular against *Streptomyces viridochromogenes*.

Structural feature

cis-dehydrodecalin core transannular oxa-bridge 12 stereocenters nine-membered lactone

Total synthesis

Branimycin Marchart, S.; Gromov, A.; Mulzer, J. Angew. Chem. Int. Ed. 2010, 49, 2050. (-> Problems)

18-deoxynargenicin A1

Plata, D. J.; Kallmerten, J. J. Am. Chem. Soc. 1988, 110, 4041.

Structural revision

Cikos, *et al.* proposed that the stereochemistry of C-17 should be *R* in 2016, <u>after the total synthesis was achieved</u>. The proposal was based on X-ray diffraction, NMR spectra (NOESY, ROESY), and conformational calculation. Cikos, A., *et al.* Org. Lett. **2016**, *18*, 780.



1. Short summary of Mulzer's route



^{2%} overall

<u>2. Answer</u>

2-A. Synthesis of decaline core 1-5









-> The reaction proceeds via π -allylcopper(III) complex, so there is no α/γ selectivity.



-> The HOMO of a bent RCu(CN)⁻ fragment is more extended in the direction opposite to the CN ligand because of its lower σ -donor ability. Since the LUMO of allyl-X is more extended on the γ position, the HOMO of RCu(CN)⁻ and γ side of π^* orbital make better interaction and it leads to $[\sigma+\pi]$ -allylcopper(III) complex. It is configurationally stable and there is no equillibrium between two types of $[\sigma+\pi]$ -allylcopper(III), so reductive elimination occurs mainly at the γ position.

syn-selective substitution: with directing groups (carbamate, phosphine, ...)





-> If the leaving group has a functional groups which can coordinates to the Cu atom, the substitution goes *syn*-selectively.

Gallina, C.; Ciattini, P. G. J. Am. Chem. Soc. 1979, 101, 1035





Discussion 3: Ni-catalyzed hydroalumination

1. Evidence for the existence of nickel hydride



Smitrovich, J. H.; Woerpel, K. A. J. Org. Chem. 1996, 61, 6044.

2-B. Formation of oxa-bridge

1-62



1-16

1-64



2-B-2. Discussion

Discussion 4: Allylic oxidation with dimethylpyrazole(DMP)-CrO3 complex



Table 1.

	reagent	time	results	-> 3,5-Dimethylpyrazole as the ligand of chromium trioxide accelerates the oxidation by inter- and intramolecular deprotonation as shown in the scheme above.
	Na ₂ CrO ₄ AcOH/Ac ₂ O	3-4 days	max 38%	
	CrO ₃ •py/CH ₂ Cl ₂ (Collins' reagent)	50 h	68%	Salmond, W. G.; Barta, M. A.; Havens, J. L. J. Org. Chem. 1978 , 43, 2057.
	$\begin{array}{c} pyH^{+}\bulletClCrO_3^{-}\left(PCC\right)\\ CH_2Cl_2 \end{array}$	-	not proceeded	e. e.g. ee., .e.e, .e., _ee
	DMP•CrO ₃ CH ₂ Cl ₂	<30 min	70-75%	

2-C. Synthesis of lactone precursor 1-10

OTBS

ÓMe

1-76a

1-76b



OTBS

OMe

1-76a



2-C-2. Discussion

Discussion 5: Selectivity on monomethylation of diol 1-9



My proposal for the explanation of the selectivity



1-74a:1-74b = 1:4



Discussion 6: Active reagent of silulation

A. Silvation only with Et₃N



B. Silyation with variable amount of Et₃N



-> Et₃N is not directly involved in the catalytic cycle,

but is merely needed to regenerate the catalyst by removing proton from it.

C. Silylation in various solvents



In DMF-d₇, basic catalyst derived from DMAP was not needed. Even without the catalyst, the reaction rate of silylation in DMF-d₇ was significantly faster than that with the catalyst in CD₂Cl₂ and CDCl₃. -> DMF itself could act as a catalyst of silylation.

The active species **1-63** had not been directly detected on ²⁹Si NMR, but further analysis with calculational prediction was performed by authors. Patschinski, P.; Zhang, C.; Zipse, H. *J. Org. Chem.* **2014**, *79*, 8348.